BOLT · Bolt Biotherapeutics

Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, and the INSPIRE platform. It serves patients, clinical investigators, and biopharmaceutical partners. The company is based in Redwood City, California.